AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.
For more information contact:
Yngvar P. Berg, CEO, +47 90044903; email@example.com
Astrid Hilde Myrset, Clinical Director, +47 93026094; firstname.lastname@example.org